



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE

1st Edition

---

# CLSI MM26™

## Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation

CLSI MM26 focuses on strategies for use of effective communication and consultation channels with clinicians in addition to test utilization management to support improved diagnosis, treatment selection, and risk assessment to guide care for patients with cancer.

---

A CLSI report for global application.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

# Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation

Daniel Jones, MD, PhD  
Honey V. Reddi, PhD, FACMG  
Jonathan Earle, MD  
Rong He, MD  
Sertac Kip, MD, PhD  
Robert F. Klees, PhD

Cates Mallaney, PhD  
Sara Brown, MS, CGC  
Vivekananda Datta, MD, PhD  
Prashant Deshpande, MBBS, MD  
Elizabeth Ostrander

## Abstract

Building, growing, and maintaining a molecular oncology testing laboratory involves extensive basic and applied knowledge in oncology, anatomic pathology, and laboratory medicine, and a diverse skill set in technical operations, test interpretation, and financial and regulatory topics. Clinical and Laboratory Standards Institute MM26—*Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation* reviews the current key concepts in molecular oncology, indications for testing, and laboratory and test design. It is intended to provide management personnel, particularly the laboratory director as well as technical and medical directors and pathologists, with practical and actionable information for strategic planning and daily laboratory operations. CLSI MM26 includes guidance focused on providing molecular oncology laboratory consultations to clinical providers and other stakeholders, including through molecular tumor boards. Emerging areas of testing such as liquid biopsy and identifying germline variants in cancer panels are also included. The infrastructure and best practices for data sharing of cancer genomic results and keeping the laboratory up-to-date with technologies and test development in the rapidly evolving areas of cancer genomics, such as single-cell sequencing and digital spatial profiling, are also discussed.

Clinical and Laboratory Standards Institute (CLSI). *Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation*. 1st ed. CLSI report MM26 (ISBN 978-1-68440-236-6 [Print]; ISBN 978-1-68440-237-3 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2024.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, and users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)



Copyright ©2024 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, or other product or material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

To read CLSI's full Copyright Policy, please visit our website at <https://clsi.org/terms-of-use/>.

## Suggested Citation

CLSI. *Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation*. 1st ed. CLSI report MM26. Clinical and Laboratory Standards Institute; 2024.

CLSI MM26-Ed1

ISBN 978-1-3440-236-6 (Print)

ISBN 978-1-68440-237-3 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 44, Number 20

## Committee Membership

### Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

### Document Development Committee on Laboratory Consult for Cancer Genetics Testing

**Daniel Jones, MD, PhD**  
**Chairholder**  
**The Ohio State University**  
**USA**

Rong He, MD  
 Mayo Clinic  
 USA

Cates Mallaney, PhD  
 PierianDx  
 USA

**Honey V. Reddi, PhD, FACMG**  
**Vice-Chairholder**  
**Belay Diagnostics**  
**USA**

Sertac Kip, MD, PhD  
 PathGroup  
 USA

Robert F. Klees, PhD  
 New York State Department of Health  
 USA

Jonathan Earle, MD  
 Hartford Pathology Associates, PC  
 USA

### Expert Panel on Molecular Diagnostics

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

### Staff

Clinical and Laboratory Standards  
 Institute  
 USA

Catherine M. Jenkins, ELS  
*Editor*

Lisa M.W. Walker, MS, ELS  
*Editor*

Katharine I. Castagna, MS, MLS(A)  
 CT, MB  
*Program Manager*

Kristy L. Leirer, MS  
*Editor*

## Acknowledgment

---

CLSI, the Consensus Council, and the Document Development Committee on Laboratory Consult for Cancer Genetics Testing gratefully acknowledge the following volunteers for their important contributions to the development of CLSI MM26.

Sara Brown, MS, CGC  
ARUP Laboratories  
USA

Prashant Deshpande, MBBS, MD  
Sultan Qaboos Comprehensive Cancer  
Care & Research Centre  
India

Elizabeth Ostrander  
Pfizer Inc.  
USA

Vivekananda Datta, MD, PhD  
Quest Diagnostics Major Laboratory  
Facilities – Marlborough  
USA

Birgit Funke, PhD, FACMG  
Icahn School of Medicine at Mount  
Sinai  
USA

Barbara Zehnbauer, PhD  
Emory University Hospital  
USA

# Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	vii
<b>Chapter 1: Introduction .....</b>	<b>1</b>
1.1 Scope .....	1
1.2 Background .....	2
1.3 Terminology .....	3
<b>Chapter 2: Principles of Tumor Classification and Types of Genomic Testing .....</b>	<b>9</b>
2.1 Classifications and Therapy Selection in Cancer .....	10
2.2 Organization of the Genome and Types of Alterations .....	16
2.3 Genetic and Epigenetic Changes in the Cancer Genome .....	19
2.4 The Molecular Diagnostic Toolkit: Assay Types and Analysis Methods .....	21
2.5 Analytics for Next-Generation Sequencing Studies: Classifying, Categorizing, and Scoring Cancer-Associated Changes .....	28
2.6 Effects of Precision Medicine on Cancer Therapy .....	31
2.7 Summary: The Integrated Cancer Diagnosis .....	32
<b>Chapter 3: Building and Growing a Cancer Testing Program .....</b>	<b>33</b>
3.1 Business Strategy .....	34
3.2 Laboratory Operations .....	38
3.3 Building a New Assay: Method Selection, Design, and Specifications .....	43
3.4 Test Launch .....	47
3.5 Example Test Process for a Comprehensive Genomic NGS Assay .....	48
<b>Chapter 4: Interpretation .....</b>	<b>49</b>
4.1 General Considerations .....	50
4.2 General Principles for Reporting Laboratory Results .....	50
4.3 Interpretative Framework for a Positive Test Result .....	57
4.4 Interpretative Framework for a Negative Test Result .....	66
4.5 Reinterpretation: Periodic Assessment of Variants of Uncertain Significance .....	68
4.6 Integration of Genetic Data into the Electronic Health Record .....	69

## Contents (Continued)

<b>Chapter 5: Maintaining and Improving a Cancer Genomics Laboratory and New Frontiers in Testing</b> . . . .	<b>71</b>
5.1 The Role of the Laboratory Director and Other Supervisory Personnel in the Laboratory . . . . .	72
5.2 Maintaining and Driving Excellence in the Laboratory . . . . .	76
5.3 Developing a Customer Satisfaction Program. . . . .	85
5.4 Positioning the Laboratory: Institutional Effect, Collaboration, and Clinical Research . . . . .	85
5.5 Integration of Laboratory Data Into Clinical Records . . . . .	88
5.6 Future of Cancer Testing: Evolving Technologies and Assay Indications. . . . .	89
<b>Chapter 6: Conclusion</b> . . . . .	<b>91</b>
6.1 Effect of Advancement in Cancer Genetics on Therapies and Assay Design . . . . .	92
6.2 Laboratory Design, Personnel, and Bioinformatic Requirements for Genomics . . . . .	92
6.3 Lifecycle and Best Practices for Development and New Test Sustainability. . . . .	93
6.4 Communicating Complex Genomics Results. . . . .	93
<b>Chapter 7: Supplemental Information</b> . . . . .	<b>95</b>
<b>References</b> . . . . .	96
<b>Appendix A.</b> Sequence Quality Metrics . . . . .	105
<b>Appendix B.</b> Databases for Evaluation and Interpretation of Germline and Somatic Variants . . . . .	108
<b>Appendix C.</b> Correlation of Functional Alterations, Biomarker, Detection Methods, and Treatments. . . . .	110
<b>Appendix D1.</b> Laboratory-Developed Test Validation. . . . .	113
<b>Appendix D2.</b> Clinical Validation Metrics. . . . .	116
<b>Appendix D3.</b> Validation Study Considerations. . . . .	117
<b>Appendix E.</b> Laboratory Director Responsibilities: Strategies for Ongoing Management . . . . .	120
<b>The Quality Management System Approach</b> . . . . .	126

## Foreword

The translation of the human genome sequencing project and basic science advances in cancer biology into oncology diagnosis and treatment over the last two decades have dramatically increased the breadth and complexity of clinical molecular diagnostics of cancer. These advances have been linked with rapid advances in sequencing technologies and the development and maturation of a range of other testing methods. Because of the varying throughput, sensitivity, and performance characteristics of these platforms, extensive knowledge is needed to select the best platform and reference content for each new oncology test. The fundamental role of bioinformatics and complex software for performance of next-generation sequencing has introduced new skill sets and validation paradigms into the clinical oncology laboratory.

In parallel with these advances, there has been increasingly stringent regulatory requirements requiring rigorous planning and documentation of molecular oncology assay validations with training and ongoing proficiency of laboratorians, bioinformatics personnel, and laboratory directors (LDs). The costs of molecular reagents and the complex multistep testing protocols warrant careful financial projections to ensure sustainable laboratory operations. This planning informs decisions on obtaining reference laboratory services and contracting services for some aspects of oncology testing.

Communicating molecular oncology results has also become more complex because germline and somatic cancer testing has expanded to include stakeholders such as genetic counselors and other medical specialists. As oncologic protocols have incorporated more molecular biomarkers into diagnostic, therapeutic, and monitoring algorithms, the need for laboratory involvement in interdisciplinary planning conferences has increased. Finally, interlaboratory data exchanges and use of public and commercial databases have become integral to somatic variant interpretation. Therefore, a holistic approach to managing the initial setup, expansion, assay selection, reporting protocols, and quality processes of the molecular oncology laboratory has become critical. CLSI MM26 provides the LD and other stakeholders with an overview of the testing and result communication processes, which are imperative to successful oncology testing.

**NOTE:** The content of this report is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### KEY WORDS

cancer biology

comprehensive reporting

laboratory design

laboratory director  
responsibilities

laboratory management

laboratory personnel  
management

quality management

sequencing technology

tumor biomarkers

variant annotation

Currently in preview, click buy full version

# Chapter ①

## Introduction

# Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation

---

## 1 Introduction

### 1.1 Scope

CLSI MM26 emphasizes the essential role of the laboratory director (LD) and/or other applicable personnel in the molecular oncology laboratory in:

- Launching well-designed and well-validated genomic assays and/or monitoring external providers for seamless delivery of testing services
- Engaging effectively with medical care personnel to accurately describe and convey the appropriate clinical indications for requesting genetic analysis for malignancies
- Ensuring accurate interpretation(s) of genetic test findings and the implications of the test results for establishing the patient's diagnosis, prognosis, and treatment selection; monitoring patient's response to therapy; and detecting cancer progression
- Ensuring awareness of the limitations of test findings, such as additional genes or variants that might not have been included in the analyses but can also contribute to the patient's condition
- Sustaining laboratory quality, innovative testing, and laboratory programs that keep pace with technologic developments and the clinical needs of the laboratory's stakeholders

CLSI MM26 does not include detailed descriptions of molecular testing methods or analytical techniques that are covered in CLSI MM01,<sup>1</sup> MM07,<sup>2</sup> MM09,<sup>3</sup> MM17,<sup>4</sup> and MM21.<sup>5</sup> Other CLSI documents provide comprehensive overviews of hematopathology (CLSI MM06<sup>6</sup>), solid tumor diagnostics (CLSI MM23<sup>7</sup>), and new molecular laboratory start-up (CLSI MM19<sup>8</sup>).

The target audience includes:

- Directors and supervisors employed by laboratories that perform cancer molecular testing
- Pathologists, scientists, and genetic counselors who are involved in selecting cancer tests and interpreting results
- LDs who are involved in developing curriculum for training purposes
- Personnel who are involved in developing cancer research protocols
- Field application specialists who work in the cancer diagnostics industry

### 1.2 Background

In the more than 50 years that genetic and genomic techniques have been applied to cancer testing, great progress has been made in understanding the molecular events underlying the initiation and progression of cancer as well as the selection of appropriate therapeutic modalities. Features that are common and different between cancers arising at different locations and with different histopathologic features have been clarified. Detection of the wide variety of molecular events now described has been facilitated by the emergence of suitable methods for detection, principally next-generation sequencing (NGS). Given the complexity of NGS

---